Oncology
Formycon AG’s clinical research includes cancer treatment in metastatic non-squamous non-small cell lung cancer (NSCLC), with interest in immuno-oncology approaches and checkpoint inhibitor therapy.
- Metastatic NSCLC
- Non-squamous lung cancer
- Immune response
The sponsor’s activity in this area reflects a focus on therapies used alongside chemotherapy for advanced lung malignancies.
Melanoma
Clinical research also covers resected melanoma, including patients with Stage IIB, Stage IIC, and Stage III disease after complete surgical removal.
- Adjuvant treatment
- Resected stage II melanoma
- Stage III melanoma
This area centers on post-surgical management of high-risk melanoma within the broader field of skin cancer.
Biologic similarity and comparative therapeutics
The sponsor’s trial portfolio includes comparison of FYB206 with Keytruda, indicating interest in biosimilar development and therapeutic equivalence in oncology.
- Comparative efficacy
- Safety
- Pharmacokinetic similarity
Research in this domain is linked to immune-based cancer therapies used across both lung cancer and melanoma settings.
Immunotherapy
Formycon AG is active in studies examining immune checkpoint therapy, with attention to treatment response in solid tumors and the clinical use of PD-1 pathway targeting agents.
- Immune-based cancer treatment
- Checkpoint inhibition
- Solid tumor therapy
This therapeutic area spans both melanoma and NSCLC, reflecting a focused oncology portfolio.
